Prevalence and trends of advanced HIV disease among antiretroviral therapy-naive and antiretroviral therapy-experienced patients in South Africa between 2010 …

MK Kitenge, G Fatti, I Eshun-Wilson, O Aluko… - BMC Infectious …, 2023 - Springer
Background Despite the significant progress made in South Africa in getting millions of
individuals living with HIV into care, many patients still present or re-enter care with …

[HTML][HTML] Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis

A Hauser, F Goldstein, ML Reichmuth… - Journal of clinical …, 2022 - Elsevier
Objective: To estimate the prevalence of NRTI and NNRTI drug resistance mutations in
patients failing NNRTI-based ART in Southern Africa. Study design: We conducted a …

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

J Dorward, R Lessells, PK Drain, K Naidoo… - The lancet HIV, 2018 - thelancet.com
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled
out in low-income and middle-income countries (LMICs). In studies from predominantly high …

Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study

A Gupta-Wright, K Fielding, JJ van Oosterhout… - The Lancet …, 2020 - thelancet.com
Background Antiretroviral therapy (ART) scale-up in sub-Saharan Africa combined with
weak routine virological monitoring has driven increasing HIV drug resistance. We …

HIV drug resistance profile in South Africa: findings and implications from the 2017 national HIV household survey

S Moyo, G Hunt, K Zuma, M Zungu, E Marinda… - PLoS …, 2020 - journals.plos.org
Background HIV drug resistance (HIVDR) testing was included in the 2017 South African
national HIV household survey. We describe the prevalence of HIVDR by drug class, age …

Viral load testing and the use of test results for clinical decision making for HIV treatment in Cameroon: An insight into the clinic-laboratory interface

G Awungafac, ET Amin, A Fualefac, NF Takah… - PLoS …, 2018 - journals.plos.org
Background The viral load (VL) in patients receiving antiretroviral therapy (ART) is the best
predictor of treatment outcome. The anticipated benefits of VL monitoring depend on the …

Long‐term virologic responses to antiretroviral therapy among HIV‐positive patients entering adherence clubs in Khayelitsha, Cape Town, South Africa: a longitudinal …

K Kehoe, A Boulle, PR Tsondai, J Euvrard… - African Journal of …, 2020 - journals.lww.com
Abstract Introduction: In South Africa, an estimated 4.6 million people were accessing
antiretroviral therapy (ART) in 2018. As universal Test and Treat is implemented, these …

Lessons in diagnostic virology: expected and unexpected sources of error

G van Zyl, J Maritz, H Newman… - Reviews in medical …, 2019 - Wiley Online Library
Viral diagnostics have shown continued innovation, with serological and molecular
diagnostic assays pushing the limits of sensitivity. Technology has provided new automated …

Drug resistance, rather than low tenofovir levels in blood or urine, is associated with tenofovir, emtricitabine, and efavirenz failure in resource-limited settings

L Jennings, T Kellermann, M Spinelli… - AIDS Research and …, 2022 - liebertpub.com
The high cost of viral load (VL) testing limits its use for antiretroviral therapy (ART)
adherence support. A low-cost lateral flow urine tenofovir (TFV) rapid assay predicts pre …

Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens

G Van Zyl, L Jennings, T Kellermann, Z Nkantsu… - AIDS, 2022 - journals.lww.com
Objective: Access to viral load measurements is constrained in resource-limited settings. A
lateral flow urine tenofovir (TFV) rapid assay (UTRA) for patients whose regimens include …